AN1901: Identification Of GLP-1 Analog Oligomeric States Using SEC-MALS

Glucagon-like peptide-1 analogs (GLP-1a), such as liraglutide and semaglutide, represent one of the fastest-growing classes of therapies, with seven FDA-approved treatments and over 50 currently in clinical trials as of 2024. Despite their promise, a significant challenge in the development, formulation, and manufacturing of these therapeutics lies in the formation of complex molecular structures—ranging from oligomers to aggregates and fibrils. These high-order structures can compromise both the safety and efficacy of the final product. Therefore, it is essential to thoroughly characterize these molecular forms to ensure proper formulation and avoid undesirable structural formations. This application note highlights the use of size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS), applied under both native and denaturing conditions, to effectively identify, quantify, and characterize monomers, oligomers, and aggregates in commercial GLP-1a products and biosimilars.

Explore how SEC-MALS can enhance your analytical workflows and ensure the integrity of your GLP-1a formulations.